ITCI Insider Trading Activity and SEC Form 4 Filings
ITCI insider trading summary
No open-market insider purchases or sales of Intra-Cellular Therapies, Inc. (ITCI) have been reported on SEC Form 4 in the past 12 months.
Latest ITCI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 5, 2024 | Sharon Mates | Chairman and CEO | Sell | $4.2M (50,163 @ $84.06) |
| Dec 5, 2024 | Sharon Mates | Chairman and CEO | Sell | $130K (1,534 @ $84.69) |
| Dec 4, 2024 | Sharon Mates | Chairman and CEO | Sell | $2.4M (27,667 @ $85.62) |
| Dec 4, 2024 | Sharon Mates | Chairman and CEO | Sell | $2.0M (23,333 @ $86.00) |
| Nov 13, 2024 | Michael Halstead | President | Sell | $475K (5,343 @ $88.92) |
| Nov 13, 2024 | Michael Halstead | President | Sell | $1.2M (13,371 @ $88.17) |
| Nov 12, 2024 | Michael Halstead | President | Sell | $548K (6,116 @ $89.63) |
| Nov 12, 2024 | Michael Halstead | President | Sell | $1.3M (15,105 @ $88.72) |
| Nov 12, 2024 | Michael Halstead | President | Sell | $150K (1,648 @ $90.89) |
| Aug 30, 2024 | Sharon Mates | Chairman and CEO | Sell | $2.1M (28,203 @ $72.73) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.